NCT06045910 - A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 7, 2024

Primary Completion Date

February 29, 2028

Study Completion Date

December 21, 2029

Conditions

Lymphoma, Non-HodgkinLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellLymphoma, FollicularLymphoma, B-CellLarge B-cell Lymphoma

Interventions

DRUG

ALETA-001

ALETA-001 will be administered intravenously (IV) every two weeks.

Trial Locations (7)

RECRUITING

University Hospital Birmingham NHS Foundation Trust, Birmingham

RECRUITING

Cambridge University Hospitals, Cambridge

RECRUITING

St James's University Hospital, Leeds

RECRUITING

University Hospital London Hospital, London

RECRUITING

Manchester Royal Infirmary, Manchester

RECRUITING

The Christie Hospital, Manchester

NOT_YET_RECRUITING

Royal Marsden Hospital, Sutton